HIGHLIGHTS
- who: Dabigatran and collaborators from the Department of Pharmacy, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China have published the research: BMC Cardiovascular Disorders on the safety of in patients with non-valvular atrial fibrillation, in the Journal: (JOURNAL)
- what: The aim of the study was to identify the impact of gene polymorphisms on the plasma concentration and clinical events of dabigatran in Chinese patients treated with DE for NVAF. All patients included in the study had received dabigatran for at least 18 continuous months and visited the clinic at least once a . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.